The recent Alzheimer story – an absolute low for the industry and especially for statisticians
End of last year, a congressional report about the approval of an Alzheimer drug by the FDA was published. It critiques both the FDA and the sponsor company Biogen. Reuters and many other major news organisations reported about it. Today, I interviewed Anja Schiel about this topic. We talked about the background of Alzheimer and its impact, incidence, and prevalence. The combination of large incidence rates, chronic condition over many years, bad prediction about what is going to happen for an individual patient (or not yet patient), and high drug prices (and other things) form the “perfect storm” for healthcare budgets. …